SubHero Banner

Trokendi XR® (topiramate) – Expanded indication

August 18, 2016 – The FDA approved Supernus Pharmaceuticals’ Trokendi XR (topiramate) extended-release capsules in patients ≥ 6 years of age as initial monotherapy for partial onset or primary generalized tonic-clonic seizures. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

Download PDF